Best Oculomotor Endpoints for Clinical Trials in Hereditary Ataxias: A Systematic Review and Consensus by the Ataxia Global Initiative Working Group on Digital‑Motor Biomarkers
- PMID: 40801974
- PMCID: PMC12350468
- DOI: 10.1007/s12311-025-01894-z
Best Oculomotor Endpoints for Clinical Trials in Hereditary Ataxias: A Systematic Review and Consensus by the Ataxia Global Initiative Working Group on Digital‑Motor Biomarkers
Abstract
Oculomotor deficits are common in hereditary cerebellar ataxias (HCAs) and their quantitative assessment offers a sensitive and reliable manner to capture disease-severity and progression. As a group of experts of the Ataxia Global Initiative to support trial readiness, we previously established harmonized methodology for quantitative oculomotor assessments in HCAs. Here, we aimed to identify to most promising oculomotor/vestibular outcomes as endpoints for future trials. Through a systematic MEDLINE search we identified 130 articles reporting oculomotor/vestibular recordings in patients with HCAs. A total of 2,018 subjects were included: 1,776 with genetically-confirmed and 242 with clinically-defined HCAs. Studied diseases included spinocerebellar ataxias (SCA) 1/2/3/6/7/27B, episodic ataxia type 2, Friedreich ataxia, RFC1-related ataxia, fragile X-associated tremor/ataxia syndrome, cerebrotendinous xanthomatosis, ataxia-telangiectasia, ataxia with oculomotor apraxia types 1&2, and Niemann-Pick disease type C. We identified up to four oculomotor/vestibular outcomes per diagnostic entity, based on their ability to robustly discriminate patients from controls, correlate with disease-severity, detect longitudinal change, and represent different disease stages. For each parameter we provide recommendations for recordings. While the implementation of quantitative assessments into clinical trials offers a unique opportunity to track dysfunction of oculomotor/vestibular networks and to assess the impact of interventions, in some HCAs, endpoint qualification of available outcomes requires further validation to characterize their reliability, sensitivity to change, and minimally important change to patients. For all HCAs for which quantitative data are scarce or lacking, there is an urgent need for prospective studies covering a broader range of oculomotor/vestibular domains as approaching new treatments require harmonized and reliable endpoints.
Keywords: Eye movement recordings; Hereditary ataxia; Oculomotor; Recommendations; Systematic review; Vestibular.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical Approval: Not applicable. Competing Interests: PG is a full-time employee of F. Hoffmann–la Roche Ltd.
Figures

Similar articles
-
Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.Cochrane Database Syst Rev. 2014 Oct 28;2014(10):CD008953. doi: 10.1002/14651858.CD008953.pub2. Cochrane Database Syst Rev. 2014. PMID: 25348587 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3. Syst Rev. 2024. PMID: 39593159 Free PMC article.
-
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21. Alzheimers Dement. 2021. PMID: 33480172 Free PMC article.
-
The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies.Neuroepidemiology. 2014;42(3):174-83. doi: 10.1159/000358801. Epub 2014 Mar 5. Neuroepidemiology. 2014. PMID: 24603320
References
-
- Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S, van de Warrenburg BP, Durr A, Klockgether T, Fancellu R. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20. 10.1212/01.wnl.0000219042.60538.92. - PubMed
-
- Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timann D, Honnorat J, Nighoghossian N, Manyam B, The Ataxia Neuropharmacology Committee of the World Federation of Neurology. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci. 1997;145:205–11. 10.1016/s0022-510x(96)00231-6. - PubMed
-
- Shaikh AG, Kim JS, Froment C, Koo YJ, Dupre N, Hadjivassiliou M, Honnorat J, Kothari S, Mitoma H, Rodrigue X, Soong BW, Subramony SH, Strupp M, Schmahmann J, Manto M. Scale for ocular motor disorders in ataxia (SODA). J Neurol Sci. 2022;443: 120472. 10.1016/j.jns.2022.120472. - PubMed
-
- Garces P, Antoniades CA, Sobanska A, Kovacs N, Ying SH, Gupta AS, Perlman S, Szmulewicz DJ, Pane C, Nemeth AH, Jardim LB, Coarelli G, Dankova M, Traschutz A, Tarnutzer AA. Quantitative oculomotor assessment in hereditary ataxia: systematic review and consensus by the Ataxia Global Initiative working group on digital-motor biomarkers. Cerebellum. 2023. 10.1007/s12311-023-01559-9. - PMC - PubMed
-
- Group. F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials